Nucleai Announces $33 Million Series B Funding from Section 32 and Sanofi Ventures

Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics.
Led by Section 32 and Sanofi Ventures, funding will enable Nucleai to expand its commercial footprint in biopharma and further develop its state-of-the-art spatial biology platform.

See article

Contact us

To request more information or to get a demo, quote for our products, please fill out the form below.

Unsubscribe at any time using the link in our emails.
For details, see our Privacy Policy.

Transforming Precision Medicine Powered by AI-pathology.

CONTACT US

Info@nucleai.ai

VISIT US

400 N Aberdeen St, Ste 951, Chicago, IL 60642, US
4 Ein Zeitim St, Tel Aviv, Israel

CONTACT US

Info@nucleai.ai

VISIT US

1375 W Fulton Ave, Chicago, IL 60607,
US Suite 650

121 Menachem Begin, 59th floor,
Tel Aviv, Israel

Transforming Precision Medicine Powered by AI-pathology.